Advances and limitations of drug delivery systems formulated as eye drops

Jumelle, Clotilde; Gholizadeh, Shima; Annabi, Nasim; Dana, Reza

doi:10.1016/j.jconrel.2020.01.057

Cited by 225 publications

(146 citation statements)

References 148 publications

Supporting

Mentioning

125

Contrasting

Unclassified

Order By: Relevance

“…The fitting could be perfect at a small time region or at a large time region but no at the whole time domain. The type of the deviation led to adding another exponential term in Equation (6). The proposed equation has the form:…”

Section: Modeling Of Drug Release Datamentioning

confidence: 99%

Chitosan Derivatives with Mucoadhesive and Antimicrobial Properties for Simultaneous Nanoencapsulation and Extended Ocular Release Formulations of Dexamethasone and Chloramphenicol Drugs

et al. 2020

View full text Add to dashboard Cite

The aim of this work was to evaluate the effectiveness of neat chitosan (CS) and its derivatives with 2-acrylamido-2-methyl-1-propanesulfonic acid (AAMPS) and [2-(methacryloyloxy)ethyl]dimethyl-(3-sulfopropyl)ammonium hydroxide (MEDSP) as appropriate nanocarriers for the simultaneous ocular administration of dexamethasone sodium phosphate (DxP) and chloramphenicol (CHL). The derivatives CS-AAMPS and CS-MEDSP have been synthesized by free-radical polymerization and their structure has been proved by Fourier-Transformed Infrared Spectroscopy (FT-IR) spectroscopy. Both derivatives exhibited low cytotoxicity, enhanced mucoadhesive properties and antimicrobial activity against Staphylococcus aureus (S.aureus) and Escherichia coli (E. coli). Encapsulation was performed via ionic crosslinking gelation using sodium tripolyphosphate (TPP) as the crosslinking agent. Dynamic light scattering measurements (DLS) showed that the prepared nanoparticles had bimodal distribution and sizes ranging from 50–200 nm and 300–800 nm. Drugs were encapsulated in their crystalline (CHL) or amorphous (DexSP) form inside nanoparticles and their release rate was dependent on the used polymer. The CHL dissolution rate was substantially enhanced compared to the neat drug and the release time was extended up to 7 days. The release rate of DexSP was much faster than that of CHL and was prolonged up to 3 days. Drug release modeling unveiled that diffusion is the main release mechanism for both drugs. Both prepared derivatives and their drug-loaded nanoparticles could be used for extended and simultaneous ocular release formulations of DexSP and CHL drugs.

show abstract

Section: Modeling Of Drug Release Datamentioning

confidence: 99%

Chitosan Derivatives with Mucoadhesive and Antimicrobial Properties for Simultaneous Nanoencapsulation and Extended Ocular Release Formulations of Dexamethasone and Chloramphenicol Drugs

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Besides its lower mucoadhesive strength, at neutral pH, CS has some additional limitations such as a low water solubility and low swelling properties. For example, the mucoadhesive strength of neat CS was estimated to 0.34 N/cm 2 [62], while PAA (Carbopol 934) had a much higher mucoadhesive strength (about 0.51 N/cm 2 ) [63]. To overcome these problems, CS has been modified with appropriate monomers, which have additional reactive groups to ensure mucoadhesion at pH 7 [64][65][66].…”

Section: Mucoadhesion Of Cs and Its Derivativesmentioning

confidence: 99%

“…Moreover, only a small volume (approximately 30 μL) of eye drop formulation can be instilled in the eye. As a result, concentrated solutions have to be administered, and frequent instillations are necessary to reach a therapeutic result [2,[9][10][11]. Systemic delivery is an alternative delivery method, yet not an ideal one as other limitations arise: first-pass metabolism, side effects, blood-ocular barriers, low eye vascularization, etc.…”

Section: Introductionmentioning

confidence: 99%

Chitosan and its Derivatives for Ocular Delivery Formulations: Recent Advances and Developments

et al. 2020

View full text Add to dashboard Cite

Chitosan (CS) is a hemi-synthetic cationic linear polysaccharide produced by the deacetylation of chitin. CS is non-toxic, highly biocompatible, and biodegradable, and it has a low immunogenicity. Additionally, CS has inherent antibacterial properties and a mucoadhesive character and can disrupt epithelial tight junctions, thus acting as a permeability enhancer. As such, CS and its derivatives are well-suited for the challenging field of ocular drug delivery. In the present review article, we will discuss the properties of CS that contribute to its successful application in ocular delivery before reviewing the latest advances in the use of CS for the development of novel ophthalmic delivery systems. Colloidal nanocarriers (nanoparticles, micelles, liposomes) will be presented, followed by CS gels and lenses and ocular inserts. Finally, instances of CS coatings, aiming at conferring mucoadhesiveness to other matrixes, will be presented.

show abstract

“…Moreover, gelatin can be applied in different forms (e.g., hydrogels) for the repair of various ocular diseases such as focal corneal wounds [87]. Gelatin nanoparticles as a DDS show merits including appropriate compatibility to ocular compartments, very low antigenicity, good mucoadhesive properties, good stability, effective lowering of the IOP, high drug bioavailability, and a lack of irritation [88][89][90]. In 2016, Mahor et al reported the use of cationic gelatin nanoparticles loaded with moxifloxacin as an effective ocular DDS in the corneal layer [91].…”

Section: Gelatinmentioning

confidence: 99%

Regulation of the Ocular Cell/Tissue Response by Implantable Biomaterials and Drug Delivery Systems

Baino

Kargozar

2020

Bioengineering

View full text Add to dashboard Cite

Therapeutic advancements in the treatment of various ocular diseases is often linked to the development of efficient drug delivery systems (DDSs), which would allow a sustained release while maintaining therapeutic drug levels in the target tissues. In this way, ocular tissue/cell response can be properly modulated and designed in order to produce a therapeutic effect. An ideal ocular DDS should encapsulate and release the appropriate drug concentration to the target tissue (therapeutic but non-toxic level) while preserving drug functionality. Furthermore, a constant release is usually preferred, keeping the initial burst to a minimum. Different materials are used, modified, and combined in order to achieve a sustained drug release in both the anterior and posterior segments of the eye. After giving a picture of the different strategies adopted for ocular drug release, this review article provides an overview of the biomaterials that are used as drug carriers in the eye, including micro- and nanospheres, liposomes, hydrogels, and multi-material implants; the advantages and limitations of these DDSs are discussed in reference to the major ocular applications.

show abstract

Advances and limitations of drug delivery systems formulated as eye drops

Cited by 225 publications

References 148 publications

Chitosan Derivatives with Mucoadhesive and Antimicrobial Properties for Simultaneous Nanoencapsulation and Extended Ocular Release Formulations of Dexamethasone and Chloramphenicol Drugs

Chitosan Derivatives with Mucoadhesive and Antimicrobial Properties for Simultaneous Nanoencapsulation and Extended Ocular Release Formulations of Dexamethasone and Chloramphenicol Drugs

Chitosan and its Derivatives for Ocular Delivery Formulations: Recent Advances and Developments

Regulation of the Ocular Cell/Tissue Response by Implantable Biomaterials and Drug Delivery Systems

Contact Info

Product

Resources

About